Back in August, the UK and American vaccine maker Novavax announced an agreement to proceed to a Phase 3 clinical trial testing that company’s COVID-19 experimental vaccine called NVX-CoV2373. This randomized, double-blind, placebo-controlled efficacy study targets 9,000 adults, aged 18-85 in the UK. Scotland’s NHS Grampian has issued a call for vaccine participation in this northeastern section of Scotland where Aberdeen Royal Infirmary (ARI), the largest hospital within the UK regional health board, serves as trial site organization for the Novavax vaccine trial. A total of 450 residents from Aberdeen and Aberdeenshire between the ages of 18 and 84 are needed for this important study. A total of 9,000 are sought after by the NHS from 18 regions across the UK as the clinical trial commences, targeting COVID-19. In the meantime, a resurgence of COVID-19 represents growing danger in Scotland, which has registered a higher death rate than the whole of the UK.
COVID-19 in Scotland
The United Kingdom (UK) has registered a total of 480,017 COID-19 cases with 43,317 deaths. After a reduction in cases, Scotland has seen cases steadily go back up. Presently, 764,178 tests have come ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).